Pharmaceutical composition comprising cyclic somatostatin analogues
Pharmaceutical compositions comprising a somastatin analogue in the form of a liquid formulation for parenteral administration are disclosed.
1. A liquid formulation for parenteral administration comprising tartaric acid and a somatostatin of formula II
wherein the configuration at C-2 is (R) or (S) or a mixture thereof, and
wherein R is NR 1 R 2 —C 2-6 alkylene or guanidine-C 2-6 alkylene, and each of R 1
R 2 independently is H or C 1-4 alkyl,
in free form, salt form, or protected form.
2. The liquid formulation according to claim 1 wherein the compound of the somatostatin is in aspartate di-salt form.
3. The liquid formulation according to claim 1 wherein the formulation is adjusted to a pH of about 4 to about 4.5.
4. The liquid formulation according to claim 1 wherein the somatostatin is cyclo[{4-(NH 2 —C 2 H 4 —NH—CO—O)Pro}-Phg-DTrp-Lys-Tyr(4-Bzl)-Phe] or a pharmaceutically acceptable salt thereof.
5. The liquid formulation according to claim 2 wherein the somatostatin is cyclo[{4-(NH 2 —C 2 H 4 —NH—CO—O)Pro}-Phg-DTrp-Lys-Tyr(4Bzl)-Phe] or a pharmaceutically acceptable salt thereof.